Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
"22.7% is not 25%, so some people were disappointed about that," he said, however adding that the firm believes there is "continued potential for developing CagriSema further," including by extending the trial period and overall dosage
Notably, only one registered clinical study exists to date, which evaluates an implant-based delivery system of Exenatide and is currently in Phase 1 with an Active, not recruiting status (NCT05670379), initiated on December 20, 2024, and expected to conclude by August 2025
In the pancreas, they enhance insulin secretion from beta cells and inhibit glucagon release from alpha cells, crucial for maintaining glucose homeostasis [34]
In the SURMOUNT-1 trial, those on 15 mg of tirzepatide lost an average of 20.9% over 72 weeks
